Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q1 2022 · 10-Q
Revenue$22.22M$22.22M+17.7% vs Q1 2021 Net Income-$76.72M-$76.72MN/M vs Q1 2021 EPS Diluted-$1.79-$1.79N/M vs Q1 2021 Operating Income-$71,527,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
Free Cash Flowderived-$66,878,000N/M Margins · derivedOperating margin-321.9%−88.7 pt vs Q1 2021
Net margin-345.3%−79.8 pt vs Q1 2021
ended Mar 31, 2022 · filed May 4, 2022 · 34 d after period end